Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 10, 2017

Deals this week: Horama, Voyager Therapeutics, Fibrocell Science

Horama SAS has raised €19m ($22m) in a series B funding round led by Fundplus, Pontifax Ltd, and IDInvest Partners. 

Horama SAS has raised €19m ($22m) in a series B funding round led by Fundplus, Pontifax Ltd, and IDInvest Partners.

The French clinical-stage biotechnology company plans to use the funds towards the development of gene therapy treatments for rare retinal diseases.

US-based biotechnology company Fibrocell Science Inc plans to raise $23m in a public offering of shares of its common stock.

Underwriters have a 30-day option to purchase additional shares to cover over-allotments if any.

Sensus Healthcare Inc plans to raise $20m through a public offering of shares of its common stock, preferred stock, warrants, stock purchase contracts and other securities.

“Underwriters have a 30-day option to purchase additional shares to cover over-allotments if any.”

The US-based medical technology company proposes to use the funds for general corporate purposes including the repurchase of common stock and financing of possible acquisitions.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Voyager Therapeutics Inc plans to issue four million shares priced at $12 a share to raise $62.1m.

The US-based clinical-stage company plans to use the funds for pre-clinical and clinical development activities and other general corporate purposes.

Swiss oncology company Nouscom AG has raised €42m ($48.79m) in a series B funding round led by Abingworth LLP.

The company plans to use the funds to advance the development of its cancer vaccine NOUS-209.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU